Pathogenetic Treatment of Gastritis as a Basis for the Prevention of Gastric Cancer in the Countries of the Commonwealth of Independent States: Literature Review and the Resolution of a Scientific Symposium Held in Minsk, Republic of Belarus, January, 27, 2018

Aim. The aim of this literature review is to generalize existing approaches to the pathogenetic treatment of gastritis as a basis for the prevention of gastric cancer, as well as to submit a resolution of a scientific symposium that brought together gastroenterologists from a number of CIS countries.

Background.  H. pylori infection is widespread in CIS countries. The proportion of infected adults in the population ranges from 60 % to over 90 %. This causes a high incidence of chronic gastritis and other diseases associated with H. pylori. In 2012, gastric cancer was recognized as the 3rd leading malignant disease in the Kyrgyz Republic and the Republic of Uzbekistan, 5th — in Belarus and Kazakhstan, 6th — in Armenia and the Russian Federation. According to the standardized cancer mortality rate, gastric cancer takes the 1st place in Kyrgyzstan and Uzbekistan, 2nd — in Belarus, 3rd — in Kazakhstan, and 4th — in Armenia and Russia. In every case of H. pylori detection, it is important to make a decision about the expediency of eradication therapy. This is particularly significant, since H. pylori eradication has been recognized as an effective method of gastric cancer prevention. In addition, H. pylori eradication therapy in patients suffering from chronic gastritis with dyspepsia symptoms serves as the firstchoice therapy that allows patients with dyspepsia resulting from H. pylori infection to be excluded. The choice of the H. pylori eradication therapy scheme is determined by the protocols (standards) of patient management accepted in the respective CIS country. A high efficacy of H. pylori infection eradication is shown to be provided by bismuthcontaining schemes.

Conclusion.  Opportunistic screening of H. pylori is carried out by general practitioners, district physicians, gastroenterologists and other specialists. The most effective method of gastric cancer prevention is the eradication therapy of H. pylori infection in chronic gastritis. The maximal positive potential of such a therapy is realized when it is performed before the atrophic changes of the gastric mucosa have appeared. 

1. Sugano K., Tack J., Kuipers E.J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–67.

2. Malfertheiner P., Meg — the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.

3. IARC Helicobacter pylori Working Group (2014). Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php

4. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):55–70. DOI: 10.22416/1382-4376-2018-28-1-55-70 [Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya E.K., Abdulkhakov R.A., Alekseyeva O.P., Alekseyenko S.A., Dekhnich N.N., Kozlov R.S., Klyaritskaya I.L., Korochanskaya N.V., Kurilovich S.A., Osipenko M.F., Simanenkov V.I., Tkachev A.V., Khlynov I.B., Tsukanov V.V. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(1):55–70. DOI: 10.22416/1382-4376-2018-28-1-55-70 (In Rus.)].

5. Ma J.L., Zhang L., Brown L.M., Li J.Y., Shen L., Pan K.F., et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488– 92. DOI: 10.1093/jnci/djs003. PMID:22271764.

6. Ford A.C.F., Forman D., Hunt R.H., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. DOI: 10.1136/ bmj.g3174. PMID:24846275.

7. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., et al. Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–7. DOI: 10.1016/S0140-6736(08)61159-9. PMID:18675689.

8. Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12(5):793–800. DOI: 10.1016/j.cgh.2013.09.057. PMID:24100112.

9. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;323:1311–15.

10. Мараховский К.Ю. Характеристика и вариантность повреждений слизистой желудка, сопряженных с колонизацией и контаминацией микробом Helicobacter pylori в детской популяции. Автореф. дис. канд. мед. наук. Минск, 2005. С 20. [Marakhovsky K.Yu. Characteristics and variation of lesions of the gastric mucosa, associated with Helicobacter pylori microbial colonization and contamination in the children’s population. Published summary of PhD in Medicine thesis. Minsk. 2005. 20 p. (In Rus.)].

11. Цаканян А.В., Алексанян Ю.Т. Эпидемиология хеликобактериозов в Республике Армения. Медицинская наука Армении НАН РА. 2009;49(2):51–56 [Tsakanyan A.V., Aleksanyan Yu.T. Epidemiology of helicobacteriosis in the Republic of Armenia. Medical Science of Armenia. 2009;49(2):51–56 (In Rus.)].

12. Решетников О.В., Курилович С.А., Кротов С.А., Кротова В.А. Хеликобактерная инфекция в сибирских популяциях. Бюл. СО РАМН 2010;30(2):88–93 [Reshetnikov O.V., Kurilovich S.A., Krotov S.A., Krotova V.A. Helicobacter pylori infection in Siberian populations. Bulletin of the Siberian Branch of the Russian Academy of Sciences 2010;30(2):88–93[In Rus.]].

13. Макаренко Е.В., Пиманов С.И., Воропаева А.В., Бондаренко В.М. Распространенность инфекции Helicobacter pylori в Витебском регионе. Вестник Витебского гос. мед. ин-та. 2005;4(4):12–19 [Makarenko E.V., Pimanov S.I., Voropaeva A.V., Bondarenko V.М. Prevalence of Helicobacter pylori infection in the Vitebsk Region. Bulletin of the Vitebsk State Medical Institute. 2005;4(4):12–19 (In Rus.)].

14. Мириджанян Г.М., Полунина Н.В. Динамика распространенности болезней органов пищеварения среди населения Республики Армения. Росс мед ж. 2017;4:172–174 [Miridzhanyan G.M., Polunina N.V. Dynamics of the prevalence of diseases of the digestive system among the population of the Republic of Armenia. Russian Medical Journal. 2017;4:172–174 (In Rus.)].

15. Лосик Е.А., Ивашкин В.Т. Патогенез аутоиммунного гастрита и факторы риска злокачественной неоплазии желудка. Рос журн гастроэнт гепатол колопроктол. 2015;25(5):81–5 [Losik E.A., Ivashkin V.T. Autoimmune gastritis: pathogenesis and risk factors for malignant transformation. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(5):81–5 (In Rus.)].

16. Тазабиев А.Н., Лапина Т.Л., Юрьева Е.Ю., Напалкова Н.Н., Тертычный А.С., Трухманов А.С., Шептулин А.А., Ивашкин В.Т. Пациент 53 лет с гастропарезом, гипергастринемией и полиповидными образованиями желудка. Рос журн гастроэнт гепатол колопроктол. 2018;28(1):94–98 DOI: 10.22416/1382-4376-2018-28-1- 94-98 [Tazabiyev A.N., Lapina T.L., Yuryeva E.Yu., Napalkova N.N., Tertychny A.S., Lemeshko Z.A., Trukhmanov A.S., Sheptulin A.A., Ivashkin V.T. Gastroparesis, hypergastrinemia and stomach polypoid lesions in 53 years patient. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(1):94–98. DOI: 10.22416/1382-4376-2018-28-1- 94-98 (In Rus.)].

17. Франк Г.А., Зайратьянц О.В., Кононов А.В., Кактурский Л.В. и Российское общество патологоанатомов. Формулировка патологоанатомического диагноза при болезнях органов пищеварения. Класс XI «Болезни органов пищеварения» МКБ-10. Клинические рекомендации. М.: Практическая медицина, 2016. С. 30. [Frank G.A., Zayratyants O.V., Kononov A.V., Kaktursky L.V. and the Russian Society of Pathoanatomists. The formulation of pathological anatomical diagnosis in diseases of the digestive system. ICD-10. Chapter XI: Diseases of the digestive system. Clinical recommendations — Moscow: Practical medicine, 2016: P. 30 (In Rus.)].

18. Клинический протокол «Диагностика и лечение пациентов с заболеваниями органов пищеварения», утвержденный Постановлением Министерства здравоохранения Республики Беларусь 01.06.2017 № 54. http://minzdrav. gov.by/upload/dadvfiles/001077_838640_54gastro.pdf [The clinical protocol «Diagnosis and treatment of patients with diseases of the digestive system», approved by the Decree of the Ministry of Health of the Republic of Belarus on 01.06.2017 No. 54 http://minzdrav.gov.by/upload/dadvfiles/001077_838640_54gastro.pdf (In Rus.)].

19. Клинический протокол по диагностике и лечению неосложненной язвенной болезни в активной фазе на первичном уровне здравоохранения Кыргызской Республики. Приказ МЗ КР № 83 от 16.02.2010. http://www. med.kg/images/MyFiles/KP/Gastroenterologya/2_kp_yazvennaya_bolezn [Clinical protocol on diagnostics and treatment of uncomplicated peptic ulcer in the active phase at the primary level of public health of the Kyrgyz Republic. The order of the Ministry of Health of the Kyrgyz Republic No. 83 of 16.02.2010. http://www.med.kg/images/MyFiles/KP/Gastroenterologya/2_kp_ yazvennaya_bolezn (In Rus.)].

20. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(2):CD002096.

21. Коровина Т.И. Клинико-инструментальная оценка эффективности последовательной эрадикационной терапии у больных эрозивно-язвенными поражениями желудка и двенадцатиперстной кишки, ассоциированными с Helicobacter pylori. Автореф. дис. ... канд. мед. наук. 2014. 24 с. [Korovina T.I. Clinical and instrumental assessment of efficacy of consecutive eradication treatment mode at Helicobacter pylori associated erosive and ulcerative lesions of the stomach and duodenum. MD degree thesis. Author’s abstract. 2014. 24 p. (In Rus.)].

22. Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Коровина Т.И., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Тер арх. 2014;8:57–61 [Samsonov A.A., Grechushnikov V.B., Andreyev D.N., Yurenev G.L., Korovina T.I., Lezhneva Yu.A., Mayev I.V. Assessment of pharmacoeconomical scores of Helicobacter pylori-associated disease treatment. Ter arkh. 2014;8:57–61 (In Rus.)].

23. Zakharova N., Savilova I. Efficacy of reinforced eradication therapy in region of high claritromycin resistance. Helicobacter. 2015;20(Suppl 1):92.

24. Щанова Н.О., Прохорова Л.В. Возможности повышения эффективности эрадикации Helicobacter pylori у больных язвенной болезнью желудка и двенадцатиперстной кишки. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(2):11–8 [Schanova N.O., Prokhorova L.V. Potential of increase of Helicobacter pylori eradication efficacy at stomach and duodenal peptic ulcer disease. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(2):11–8 (In Rus.)].

25. Bagchi D., McGinn T.R., Ye H., et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci. 1999;44(12):2419–2428.

26. Кононов А.В., Мозговой С.И., Рыбкина Л.Б., Бунова С.С., Шиманская А.Г. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Рос журн гастроэнтерол гепатол колопроктол 2006;16(6):21–8 [Kononov A.V., Mozgovoy S.I., Rybkina L.B., Bunova S.S., Shimanskaya A.G. Estimation of bismuth tripotassium dicitrate cytoprotective effect on stomach mucosa at H. pylori eradication and prolonged drug administration. Rus J Gastroenterol Hepatol Coloproctol. 2006;16(6):21–8 (In Rus.)].